Brentuximab Vedotin (Bv)

DRUG5 trials

Conditions

Brentuximab VedotinCutaneous T Cell Lymphoma (CTCL)Cutaneous T-Cell Lymphoma/Mycosis FungoidesHodgkin LymphomaHodgkin Lymphoma (Category)Peripheral T-cell LymphomaPrimary Cutaneous Anaplastic Large Cell Lymphoma

Phase 2

BV After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03540849

University Hospital, CaenHodgkin Lymphoma

Start: 2018-03-07End: 2023-03-07Target: 58Updated: 2018-05-30

Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)

Not yet recruitingNCT07717580

Peking University First HospitalCutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma

Start: 2026-07-31End: 2028-12-30Target: 46Updated: 2026-07-23

Phase 3

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

Not yet recruitingNCT07178457

Assistance Publique - Hôpitaux de ParisCutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin

Start: 2025-11-01End: 2032-11-01Target: 84Updated: 2025-09-17

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Enrolling by invitationNCT07258680

N.N. Petrov National Medical Research Center of OncologyPeripheral T-cell Lymphoma

Start: 2013-10-31End: 2028-12-31Target: 114Updated: 2025-12-02

Phase 4

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Not yet recruitingNCT06761911

Xiuhua SunHodgkin Lymphoma (Category)

Start: 2024-12-31End: 2026-01-31Target: 100Updated: 2025-01-07

Related Papers

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma